Multiple Myeloma | Specialty

FDA Approves Third Daratumumab Triplet for Myeloma

June 16th 2017

The FDA has approved daratumumab for use in combination with pomalidomide and dexamethasone for patients with multiple myeloma who have received at least 2 prior therapies, including a proteasome inhibitor and lenalidomide.

Dr. Jagannath on Mechanism of Action of Selinexor in Myeloma

June 16th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the mechanism of action of selinexor and its efficacy in multiple myeloma and other tumor types.

Merck Pauses Enrollment in 2 Pembrolizumab Myeloma Trials

June 13th 2017

Merck announced that it is postponing enrollment in the phase III KEYNOTE-183 and KEYNOTE-185 trials because of deaths in patients with multiple myeloma assigned to pembrolizumab (Keytruda), the company's blockbuster anti-PD-1 therapy.

Dr. Jakubowiak on Phase I Daratumumab Regimens in Newly Diagnosed Multiple Myeloma

June 12th 2017

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, The University of Chicago Medicine, discusses a phase I study of daratumumab (Darzalex) in combination with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma.

Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma

June 9th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

BCMA CAR T-Cell Therapy Yields High Remission Rate in Multiple Myeloma

June 6th 2017

Early results from a Chinese study showed that 33 of 35 patients (94%) with relapsed or refractory multiple myeloma experienced clinical remission after treatment with chimeric antigen receptor T cells targeting B-cell maturation protein.

Dr. Shain Discusses Emerging Agents in Multiple Myeloma

May 26th 2017

Kenneth H. Shain, MD, PhD, assistant member, Moffitt Cancer Center, discusses emerging agents in multiple myeloma.

Dr. Baz on Varying Treatment Approaches for Patients With Multiple Myeloma

May 26th 2017

Rachid Baz, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses how treatment approaches vary for patients with multiple myeloma.

Dr. Kumar Discusses Daratumumab in Multiple Myeloma

May 18th 2017

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab in multiple myeloma.

Expert Highlights Evolving Approaches for Newly Diagnosed Multiple Myeloma

May 16th 2017

Prashant Kapoor, MD, discusses the importance of minimal residual disease negativity, using International Myeloma Working Group criteria, and field-changing pivotal data in multiple myeloma.

Kumar Recaps Ongoing Advances in Myeloma

May 13th 2017

Shaji Kumar, MD, discusses novel therapies for patients with multiple myeloma in detail, the sequencing challenges ahead, and which current agents pose the greatest challenge.

Next Steps in Myeloma Include Combo Regimens and Achieving MRD

May 10th 2017

Ruben Niesvizky, MD, discusses some of the exciting advances, the potential of chimeric antigen receptor T-cell therapy, and emerging combination regimens on the horizon in multiple myeloma.

Dr. Niesvizky on Exciting Changes in the Multiple Myeloma Landscape

May 8th 2017

Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses some of the exciting changes that have occurred in the field of multiple myeloma.

Dr. Kapoor on Advice for Oncologists Treating Patients With Myeloma

May 4th 2017

Prashant Kapoor, MD, hematologic oncologist, Mayo Clinic, shares advice for community oncologists who are treating patients with multiple myeloma.

Dr. Kumar on Potential of CAR T-Cell Therapy in Multiple Myeloma

May 2nd 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.

EU Approves Daratumumab Triplets for Myeloma

May 1st 2017

The European Commission has approved daratumumab for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma following at least 1 prior therapy.

Novel Agents for Multiple Myeloma

April 28th 2017

Emerging Combination Therapies for Myeloma

April 28th 2017

Therapy Choice at Myeloma Progression

April 28th 2017

Treatment for Relapsed/Refractory Multiple Myeloma

April 28th 2017